Modern approaches to the management of patients with diabetic nephropathy
DOI:
https://doi.org/10.58676/sjmas.v3i5.124Keywords:
Precision medicine, Renal biomarkers, SGLT2 inhibitors, Chronic kidney disease (CKD), Diabetic nephropathyAbstract
Background: Diabetic nephropathy (DN), a major complication of diabetes mellitus, is one of the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide. The increasing global burden of diabetes, especially in low- and middle-income countries, has led to a parallel rise in diabetic kidney disease. This study reviews current evidence-based strategies for the diagnosis, prevention, and management of DN, highlighting recent advances in pharmacological therapies, biomarker discovery, and the integration of precision medicine.
Methods and Materials: This project employed a comprehensive literature review using reputable databases including PubMed, Cochrane Library, Scopus, and guidelines from KDIGO and the American Diabetes Association. The methodology also involved synthesis of clinical trial data, expert consensus documents, and emerging research on novel therapeutic targets and biomarkers. Practical recommendations were developed through analysis and comparative evaluation of diagnostic and treatment algorithms.
Results: Findings indicate that DN pathogenesis is multifactorial, involving hyperglycemia, oxidative stress, and dysregulated hemodynamics. Key diagnostic tools such as urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and emerging biomarkers (e.g., NGAL, KIM-1, and urinary nephrin) enhance early detection. Novel pharmacotherapies demonstrate renoprotective and cardioprotectiveincluding SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal MRAs (e.g., finerenone). Lifestyle modifications and precision medicine approaches further optimize patient outcomes.
Conclusion: The management of diabetic nephropathy requires a multidisciplinary, personalized, and evidence-based approach. Integration of early biomarkers, individualized glycemic and blood pressure control, RAAS inhibition, and new therapeutic agents can significantly delay disease progression and reduce cardiovascular risk. Future directions should emphasize precision medicine, continued research on novel agents, and collaborative care models to improve long-term outcomes in DN patients.
References
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). Diabetic kidney disease. Clinical Journal of the American Society of Nephrology, 12(12), 2032–2045. https://doi.org/10.2215/CJN.11491116
AlQudah, M., Hale, T. M., & Czubryt, M. P. (2020). Targeting the renin-angiotensin-aldosterone system in fibrosis. Matrix Biology, 91–92, 92–108. https://doi.org/10.1016/j.matbio.2020.04.005
American Diabetes Association. (2022). Classification and diagnosis of diabetes: Standards of medical care in diabetes—2022. Diabetes Care, 45(Supplement_1), S17–S38. https://doi.org/10.2337/dc22-S002
Baigent, C., Landray, M. J., Reith, C., et al. (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection). The Lancet, 377(9784), 2181–2192. https://doi.org/10.1016/S0140-6736(11)60739-3
Bakris, G. L., Agarwal, R., Anker, S. D., et al. (2020). Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. The New England Journal of Medicine, 383(23), 2219–2229. https://doi.org/10.1056/NEJMoa2025845
Bjornstad, P., Cherney, D. Z., Maahs, D. M., & Nadeau, K. J. (2016). Diabetic kidney disease in adolescents with type 2 diabetes: New insights. Current Diabetes Reports, 16(2), Article 11. https://doi.org/10.1007/s11892-015-0708-0
Cai, L., Huang, Y., Li, X., Cao, D., & Liu, F. (2024). Effects of dietary intervention on diabetic nephropathy: An umbrella review of systematic reviews and meta-analyses of randomized controlled trials. Frontiers in Endocrinology, 15. https://doi.org/10.3389/fendo.2024.1385872
Chen, S., Chen, L., & Jiang, H. (2022). Prognosis and risk factors of chronic kidney disease progression in patients with diabetic kidney disease and non-diabetic kidney disease: A prospective cohort CKD-ROUTE study. Renal Failure, 44(1), 1309–1318. https://doi.org/10.1080/0886022X.2022.2106872
Cheng, D., Fei, Y., Liu, Y., et al. (2014). HbA1C variability and the risk of renal status progression in diabetes mellitus: A meta-analysis. PLOS ONE, 9(12), e115509. https://doi.org/10.1371/journal.pone.0115509
Dai, Y., Quan, J., Xiong, L., Luo, Y., & Yi, B. (2022). Probiotics improve renal function, glucose, lipids, inflammation and oxidative stress in diabetic kidney disease: A systematic review and meta-analysis. Renal Failure, 44(1), 862–880. https://doi.org/10.1080/0886022X.2022.2079522
De Boer, I. H., Khunti, K., Sadusky, T., et al. (2022). Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care, 45(12), 3075–3090. https://doi.org/10.2337/dci22-0027
Downie, M. L., Desjarlais, A., Verdin, N., Woodlock, T. J., & Collister, D. (2023). Precision medicine in diabetic kidney disease: A narrative review framed by lived experience. Canadian Journal of Kidney Health and Disease, 10, 20543581231209012. https://doi.org/10.1177/20543581231209012
Graham, G. G., Punt, J., Arora, M., et al. (2011). Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics, 50(2), 81–98.
Hager, M. R., Narla, A. D., & Tannock, L. R. (2016). Dyslipidemia in patients with chronic kidney disease. Reviews in Endocrine and Metabolic Disorders, 18(1), 29–40. https://doi.org/10.1007/s11154-016-9402-z
Heerspink, H. J. L., Parving, H. H., Andress, D. L., et al. (2019). Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial. The Lancet, 393(10184), 1937–1947. https://doi.org/10.1016/S0140-6736(19)30772-X
Hodson, E. M., & Cooper, T. E. (2023). Altered dietary salt intake for preventing diabetic kidney disease and its progression. Cochrane Database of Systematic Reviews, 2023(1), CD006763. https://doi.org/10.1002/14651858.CD006763.pub3
Hou, Y. C., Lu, C. L., & Lu, K. C. (2018). Mineral bone disorders in chronic kidney disease. Nephrology, 23, 88–94. https://doi.org/10.1111/nep.13457
International Diabetes Federation. (2023). Diabetes facts & figures. https://idf.org/about-diabetes/diabetes-facts-figures/
Kaul, A., Behera, M., Rai, M., et al. (2018). Neutrophil gelatinase-associated lipocalin: As a predictor of early diabetic nephropathy in type 2 diabetes mellitus. Indian Journal of Nephrology, 28(1), 53–58. https://doi.org/10.4103/ijn.IJN_96_17
Keith, A., Betts, P., Song, J., Faust, E., et al. (2021). Medical costs for managing chronic kidney disease and related complications in patients with chronic kidney disease and type 2 diabetes. The American Journal of Managed Care, 27(20). https://www.ajmc.com/view/medical-costs-for-managing-chronic-kidney-disease-and-related-complications-in-patients-with-chronic-kidney-disease-and-type-2-diabetes
Kishore Kondapi, N., Lakshmana Kumar, N., Moorthy, S., & Silambanan, S. (2021). A study of association of urinary nephrin with albuminuria in patients with diabetic nephropathy. Indian Journal of Nephrology, 31(2), 142. https://doi.org/10.4103/ijn.IJN_305_19
Kumar, M., Dev, S., Khalid, M. U., et al. (2023). The bidirectional link between diabetes and kidney disease: Mechanisms and management. Cureus, 15(9), e45615. https://doi.org/10.7759/cureus.45615
Levey, A. S., Eckardt, K. U., Dorman, N. M., et al. (2020). Nomenclature for kidney function and disease—Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. European Heart Journal, 41(48), 4592–4598. https://doi.org/10.1093/eurheartj/ehaa650
Liao, X., Zhu, Y., & Xue, C. (2022). Diagnostic value of serum cystatin C for diabetic nephropathy: A meta-analysis. BMC Endocrine Disorders, 22(1), Article 145. https://doi.org/10.1186/s12902-022-01052-0
Looker, H. C., Colombo, M., Hess, S., et al. (2015). Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney International, 88(4), 888–896. https://doi.org/10.1038/ki.2015.199
Macdougall, I. C. (2023). Anaemia in CKD – Treatment standard. Nephrology, Dialysis, Transplantation. Advance online publication. https://doi.org/10.1093/ndt/gfad250
Natale, P., Palmer, S. C., Tunnicliffe, D. J., Toyama, T., & Strippoli, G. F. M. (2023). Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database of Systematic Reviews, 2023(8), CD015906. https://doi.org/10.1002/14651858.CD015906
Potenza, M., Gagliardi, S., Nacci, C., Carratu, M., & Montagnani, M. (2011). Endothelial dysfunction in diabetes. Current Medicinal Chemistry, 16(1), 94–112. https://doi.org/10.2174/092986709787002853
Samsu, N. (2021). Diabetic nephropathy: Challenges in pathogenesis, diagnosis, and treatment. BioMed Research International, 2021, Article 1497449. https://doi.org/10.1155/2021/1497449
Taler, S. J., Agarwal, R., Bakris, G. L., et al. (2013). KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. American Journal of Kidney Diseases, 62(2), 201–213. https://doi.org/10.1053/j.ajkd.2013.03.018
The EMPA-KIDNEY Collaborative Group. (2022). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), 117–127. https://doi.org/10.1056/NEJMoa2204233
Thomas, B. (2019). The global burden of diabetic kidney disease: Time trends and gender gaps. Current Diabetes Reports, 19(4), Article 18. https://doi.org/10.1007/s11892-019-1133-6
Tuttle, K. R., Brosius, F. C., Adler, S. G., et al. (2018). JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease. Nephrology, Dialysis, Transplantation, 33(11), 1950–1959. https://doi.org/10.1093/ndt/gfx377
Umanath, K., & Lewis, J. B. (2018). Update on diabetic nephropathy: Core curriculum 2018. American Journal of Kidney Diseases, 71(6), 884–895. https://doi.org/10.1053/j.ajkd.2017.10.026
Wagnew, F., Eshetie, S., Kibret, G. D., et al. (2018). Diabetic nephropathy and hypertension in diabetes patients of sub-Saharan countries: A systematic review and meta-analysis. BMC Research Notes, 11(1), 565. https://doi.org/10.1186/s13104-018-3670-5
Wanner, C., Inzucchi, S. E., Lachin, J. M., et al. (2016). Empagliflozin and progression of kidney disease in type 2 diabetes. New England Journal of Medicine, 375(4), 323–334. https://doi.org/10.1056/NEJMoa1515920
Zhu, H., Jiang, Z., Gong, P., et al. (2018). Efficacy of low-protein diet for diabetic nephropathy: A systematic review of randomized controlled trials. Lipids in Health and Disease, 17(1), 141. https://doi.org/10.1186/s12944-018-0791-8
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Vaibhav Gumber, Dr. Ghassan Salibi, Prof Nikolaos Tzenios
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
